Evidence map›Paper›PMID 37759099›Full record

ArticleDermatology and therapy2023

Durability of Near-Complete Skin Clearance in Patients with Psoriasis Using Systemic Biologic Therapies: Real-World Evidence from the CorEvitas Psoriasis Registry.

Robert R McLean, Adam P Sima, Silky Beaty, Eric A Jones, Thomas Eckmann, Robert Low, Laura McClung, Rebecca L Spitzer, Jeffrey Stark, April Armstrong

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dermatology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02707341 (CorEvitas Psoriasis), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02707341 recruitingnot on this map

CorEvitas Psoriasis (PSO) Registry

Typeobservational_patient_registrySponsorCorEvitasRan2015 to 2100Enrolled10,000ConditionsPsoriasis
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Robert R McLeanCorEvitas, LLC, 1440 Main Street, Waltham, MA, 02130, USA. rmclean@corevitas.com.
Adam P SimaCorEvitas, LLC, 1440 Main Street, Waltham, MA, 02130, USA.
Silky BeatyUCB Pharma, Smyrna, GA, USA.
Eric A JonesCorEvitas, LLC, 1440 Main Street, Waltham, MA, 02130, USA.
Thomas EckmannCorEvitas, LLC, 1440 Main Street, Waltham, MA, 02130, USA.
Robert LowUCB Pharma, Smyrna, GA, USA.
Laura McClungUCB Pharma, Smyrna, GA, USA.
Rebecca L SpitzerCorEvitas, LLC, 1440 Main Street, Waltham, MA, 02130, USA.
Jeffrey StarkUCB Pharma, Smyrna, GA, USA.
April ArmstrongKeck School of Medicine at the University of Southern California, Los Angeles, CA, USA.
Navitas Systems (United States) · USUCB Pharma (United States) · USUniversity of Southern California · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionNear-complete skin clearance has become a rapidly achievable treatment goal for patients with psoriasis receiving systemic biologic therapies. However, real-world evidence for durability of near-complete skin clearance and risk factors associated with loss of near-complete skin clearance is limited.

methodsThis study described durability of near-complete skin clearance (≥ 90% improvement in Psoriasis Area and Severity Index from initiation; PASI90) and identified clinical factors or patient characteristics associated with loss of PASI90 among patients with psoriasis from the CorEvitas Psoriasis Registry (April 2015-August 2021). Included patients had PASI > 5 at biologic initiation and achieved PASI90 at approximately 6 months from initiation (index). A Kaplan-Meier estimate described time to loss of treatment response over 24 months follow-up from index. Proportional hazards regression was used to identify independent predictors of loss of treatment response.

resultsThis study included 687 patient initiations (instances of patients initiating a biologic). Following achievement of PASI90, treatment response was maintained in more than half of patient initiations (54%). Treatment response was maintained at 6, 12, and 18 months from index in an estimated 73% (95% [confidence interval] CI 70-77%), 60% (95% CI 56-63%), and 50% (95% CI 47-54%) of patient initiations, respectively. Adjusted hazards regression suggested non-White race, full-time employment, greater body weight, concomitant psoriatic arthritis, prior use of biologics, and clinically meaningful skin symptoms were associated with loss of treatment response.

conclusionsAmong real-world patients with psoriasis who achieved PASI90 with biologic therapy, about one-quarter lost response at 6 months, and half lost response at 18 months. Prior use of a biologic therapy and clinically meaningful skin symptoms at index, including itch and skin pain, were associated with loss of treatment response. Therefore, dermatologists may consider focusing on patient-reported symptoms as part of any intervention designed to reduce the likelihood of loss of response to biologic therapies.

trial registrationClinicalTrials.gov identifier, NCT02707341.

Indexed as

Biologic therapyCorEvitas Psoriasis RegistryInterleukinPASIPsoriasisReal-world evidenceSkin clearance

Identifiers

PMID37759099
PMCPMC10613189
OpenAlexW4387095118

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.